Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OrbusNeich Medical Group Holdings Limited ( (HK:6929) ) has issued an update.
OrbusNeich Medical Group Holdings Limited has scheduled a board meeting for March 12, 2026 to review and approve the annual results for the year ended December 31, 2025, and to consider the publication of those results. The board will also deliberate on the potential declaration of a final dividend and handle other corporate matters, a process that will be closely watched by investors for signals on the company’s financial performance and shareholder return policy.
The announcement also confirms the current composition of the board, which includes a mix of executive, non-executive and independent non-executive directors, underscoring the company’s adherence to corporate governance practices. The forthcoming results and any dividend decision could influence market perceptions of the company’s operational momentum and its commitment to rewarding shareholders.
The most recent analyst rating on (HK:6929) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on OrbusNeich Medical Group Holdings Limited stock, see the HK:6929 Stock Forecast page.
More about OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited is a Hong Kong-listed medical device company focused on cardiovascular intervention technologies. The group develops and markets products used in interventional cardiology procedures, serving hospitals and clinicians in markets that require advanced treatment solutions for heart and vascular diseases.
Average Trading Volume: 129,549
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.97B
For detailed information about 6929 stock, go to TipRanks’ Stock Analysis page.